Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

摘要: copies/mL. All patients had resistance mutations to at least two drug classes, although only 9.3% specific darunavir. A darunavir-based regimen was started in 47 (78.4%) patients, combined with etravirine (26.7%), tenofovir (26.7%) or raltegravir (25%). Three (5%) discontinued treatment due side effects. At the end of follow-up, 86.7% remained free therapeutic failure; percentages no failure weeks 24, 48 and 96 were 96.6% (95% CI, 91.9‐101.3); 90.1% 81.9‐98.3) 79.8% 66.1‐93.5), respectively. Conclusions: Our results suggest that a dual-therapy rescue including PI/r is convenient, well tolerated potent enough achieve persistent viral suppression selected pre-treated low load few PI mutations.